Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3655079
Max Phase: Preclinical
Molecular Formula: C15H23N3O3
Molecular Weight: 293.37
Molecule Type: Small molecule
Associated Items:
ID: ALA3655079
Max Phase: Preclinical
Molecular Formula: C15H23N3O3
Molecular Weight: 293.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C1c2[nH]cnc2CCN1C(=O)OCC1CCOC1
Standard InChI: InChI=1S/C15H23N3O3/c1-10(2)14-13-12(16-9-17-13)3-5-18(14)15(19)21-8-11-4-6-20-7-11/h9-11,14H,3-8H2,1-2H3,(H,16,17)
Standard InChI Key: YYEWOALXGQHVJR-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 293.37 | Molecular Weight (Monoisotopic): 293.1739 | AlogP: 2.14 | #Rotatable Bonds: 3 |
Polar Surface Area: 67.45 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.22 | CX Basic pKa: 6.16 | CX LogP: 0.95 | CX LogD: 0.93 |
Aromatic Rings: 1 | Heavy Atoms: 21 | QED Weighted: 0.93 | Np Likeness Score: -0.29 |
1. (2015) Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds, |
2. (2013) Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds, |
3. (2016) 4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds, |
Source(1):